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Antimicrobial-resistant Escherichia coli are a concern for military health services. We studied 100 extended-
spectrum beta-lactamase (ESBL)-producing and non-producing E. coli clinical and surveillance isolates frommil-
itary personnel and civilians at Brooke Army Medical Center (2007–2011). Major E. coli lineages, most promi-
nently ST10 (24%), ST131 (16%), and ST648 (8%), were distributed much as reported for other North American
populations. ST131, representedmainly by its resistance-associated ST131-H30 clonal subset, was uniquely asso-
ciated with a clinical origin, regardless of ESBL status. Thus, clonal background predicted resistance phenotype
and clinical versus surveillance origin, and these findings could assist military clinicians and epidemiologists.
Published by Elsevier Inc.
1. Introduction
Extraintestinal pathogenicEscherichia coli (ExPEC) causemost communi-
ty and hospital-associated extraintestinal E. coli infections (Johnson and
Russo, 2005). Specific ExPEC lineages, or sequence types (STs), are common-
ly multidrug-resistant (MDR), and have been associated with international
travel and medical care. The acquisition of difficult-to-treat, antimicrobial-
resistant ExPEC is therefore a concern for military health services.
In this study, we examined the distribution of E. coli genotypes iden-
tified among clinical and surveillance (e.g. skin colonization) isolates
from deployed and non-deployed active duty US military personnel
and civilians, collected as part of routine medical care at a USmilitary
medical center. Stool surveillance isolates were not included in this
study. We sought to determine whether military personnel (especially
those with a history of international deployment or injury), when in-
fected or colonized cutaneously with E. coli, were at an increased risk
of having specific extensively drug-resistant major lineages of ExPEC.
In addition, we attempted to define the characteristics of these lineages
as they occur among military personnel. We focused specifically on the
presence of sequence type 131 (ST131) and its resistance-associated
H30 and H30Rx subclones within this population, and compared these
strains” prevalence with data collected from veterans receiving care
within the VeteransHealth Administration in 2011 (Colpan et al., 2013).
2. Materials and methods
2.1. Isolates and subjects
The study isolates included 100 de-identified archival E. coli clinical and
surveillance isolates, whichwere obtained alongwith associated information
(specimen type, collection date, collection site, isolate source, injury during
deployment, etc.) from the Molecular Biology Laboratory at Brooke Army
Medical Center, JBSA Fort SamHouston, TX. The isolates had been recovered
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between2007and2011 from100uniquemilitary personnel and civilians at-
tending the samemilitary medical center (Table 1) and had been tested for
extended-spectrum beta-lactamase (ESBL) production, as described below.
The archival collections included isolates from patients with a suspected in-
fection (clinical) or who were being screened for antimicrobial-resistant
E. coli from nares or groin skin sites (surveillance). The 100 study isolates
were selected randomly as four groups of 25 isolates each: (i) ESBL-
producing clinical isolates, (ii) non-ESBL-producing clinical isolates, (iii)
ESBL-producing surveillance isolates, and (iv) non-ESBL-producing surveil-
lance isolates (Table 1). Specimen type and the subject’smilitary versus civil-
ian status and deployment history did not influence isolate selection.
The study was approved by research oversight committees at the
participating institutions. It did not qualify for review by the respective
institutional review boards due to its use of archived isolates that had
been collected for routine monitoring purposes, along with generic
deidentified epidemiological data.
2.2. Laboratory analysis
Antimicrobial susceptibilities and ESBL production was determined
using the BD Phoenix AutomatedMicrobiology System (BectonDickinson
and Company, Sparks, MD, USA) per manufacturer guidelines utilizing
NMIC/ID-123 panels. Minimum inhibitory concentration (MIC) results
were interpreted according to the Clinical Laboratory and Standards Insti-
tute criteria (Clinical and Laboratory Standards Institute, 2013). In addi-
tion, isolates were assessed molecularly for blaCTX-M-15, major E. coli
phylogenetic group (phylogroup) (Clermont et al., 2013), ST or ST com-
plex (STc; as determined by fumC-fimH typing (Weissman et al., 2012),
full or partial MLST (Maiden et al., 1998), or STc-specific PCR assays
(Clermont et al., 2014; Johnson et al., 2009; Matsumura et al., 2012)),
membership in the ST131-H30 clonal subset or its sublineage ST131-
H30Rx (Banerjee et al., 2013), O type (O16 and O25b only) (Johnson
et al., 2014), and extended virulence genotype (for 50 markers)
(Johnson et al., 2015). Resistance scores were defined as the number of
antibiotic classes towhich an isolate exhibited resistance. Virulence scores
were defined based on the raw count of detected virulence genes.
2.3. Statistical analysis
Comparisons of proportions were tested using Fisher's exact or chi-
squared tests. Comparisons of scores were tested using the Wilcoxon
rank-sum test.
3. Results
3.1. Clinical and epidemiological data
The 100 source subjects included 84 (84%) active duty military per-
sonnel and 16 (16%) civilians receiving care at Brooke Army Medical
Center (Table 1). Of 65 subjects with a known injury, 49 (75%) were in-
jured during military deployment, which occurred exclusively in Iraq
and/or Afghanistan. E. coli isolates recovered from these 49 deployed
and injured military members included 10 isolates from wound sites,
2 fromblood and 37 collected from the groin area, as part of surveillance
sampling. The 50 clinical isolates were from urine (n=18), blood (n=
8), wound (n=23), and bodyfluid (n=1). The 50 surveillance isolates
were from groin (n = 49) and nares (n = 1).
3.2. Phylogroups
The 4 most common E. coli phylogroups overall, in descending fre-
quency, were B2 (31%), A (30%), D (16%), and B1 (13%) (Table 1).
Phylogroup B2 isolateswere uniquely over-represented among the clin-
ical isolates. Phylogroup A isolates (specifically ST10), although some-
what more common among surveillance than clinical isolates, were
more common among clinical isolates than expected based on prior
work (Salipante et al., 2015).
3.3. Sequence Types
The 8most common STs, in descending frequency, were ST10 (24%),
ST131 (16%), ST648 (8%), ST38 (5%), ST95 (5%), ST69 (4%), ST405 (4%),
and ST73 (3%). Collectively, these 8 predominant STs accounted for 69%
of the population. No temporal prevalence trendswere apparent for any
specific STs (not shown).
Statistical comparisons were done only with the 3 most common
STs. ST10 was under-represented among non-ESBL-producing clinical
isolates, whereas ST648 was over-represented among ESBL-producing
surveillance isolates and absent among non-ESBL surveillance isolates.
The combined prevalence of the three most common STs (ST10, 131,
and 648) varied by host group, i.e., 36/84 (43%) for active duty subjects
(including 24/49 [49%] for subjects with deployment-related wounds),
versus 12/16 (75%) for civilian subjects (p = 0.02).
ST131, themost prevalent ST among clinical isolates, was the only ST
that was significantly over-represented among clinical isolates as
Table 1
Extraintestinal pathogenic Escherichia coli source and characteristics.
Prevalence of trait, No. of isolates (%)
Clinical Surveillance
Host characteristic,
phylogroup, or STa
Total
(n = 100)
ESBL-producing
(n = 25)
Non-ESBL-producing
(n = 25)
ESBL-producing
(n = 25)
Non-ESBL-producing
(n = 25)
P valueb
Active duty 84 (84) 18 (72) 20 (80) 22 (88) 24 (96) 0.11
Deployment injury 65 (65) 11 (44) 1 (4) 19 (76) 18 (72) b0.001
Group A 30 (30) 8 (32) 4 (16) 10 (40) 8 (32) 0.31
Group B1 13 (13) 2 (8) 3 (12) 3 (12) 5 (20) 0.73
Group B2 31 (31) 8 (32) 14 (56) 2 (8) 7 (28) 0.003
Group C 2 (2) 1 (4) 1 (4) 0 (0) 0 (0) n.a.c
Group D 16 (16) 5 (20) 1 (4) 5 (20) 5 (20) 0.26
Group F 8 (8) 1 (4) 2 (8) 5 (20) 0 (0) 0.08
ST10 (group A) 24 (24) 8 (32) 1 (4) 7 (28) 8 (32) 0.06
ST131 (group B2) 16 (16) 8 (32) 6 (24) 1 (4) 1 (4) 0.01
ST131 H30 14 (14) 6 (24) 6 (24) 1 (4) 1 (4) 0.60
ST131 H30Rx 8 (8) 4 (16) 3 (12) 0 (0) 1 (4) n.a.c
ST131 non-H30 2 (2) 2 (8) 0 (0) 0 (0) 0 (0) n.a.c
ST648 (group F) 8 (8) 1 (4) 2 (8) 5 (20) 0 (0) n.a.c
a ST = sequence type. Only the three most prevalent STs are shown. Other STs that accounted for ≥3% of isolates each, in order of descending overall prevalence (no. of isolates), in-
cluded: ST38 (5%), ST95 (5%), ST69 (4%), ST405 (4%), and ST73 (3%).
b By Fisher's exact test (two-tailed), for four-group comparisons.
c n.a., not applicable (number too small for statistical analysis).
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comparedwith surveillance isolates, regardless of ESBL status (Table 1).
Fourteen (88%) of the 16 ST131 isolates belonged to the H30 subclone,
with 8 (50%) of the H30 isolates belonging to the H30Rx sublineage.
All ST131 isolates were O25b-positive except for one, which was non-
H30 and O16-positive. ST131, H30, and H30Rx isolates were similarly
prevalent among clinical isolates from active duty personnel versus ci-
vilians, and from subjects with deployment-related injuries versus
other sources (not shown).
3.4. blaCTX-M-15
Overall, 31 (62%)of the50ESBL-producing isolates containedblaCTX-M-15,
which was similarly prevalent among clinical and surveillance isolates
(14/25 [56%] versus 17/25 [68%]: p = 0.38). blaCTX-M-15 was not associ-
ated with active duty status or deployment injury (not shown). ST131
accounted for 7 (14%) ESBL-producing and 5 (16%) blaCTX-M-15-
carrying isolates, with the majority of these belonging to the H30Rx
ST131 subclone. In contrast, ST10 accounted for 15 (30%) ESBL-
producing and 12 (39%) blaCTX-M-15-carrying isolates.
3.5. Virulence Scores
Overall, virulence scores were higher among non-ESBL-producers
than ESBL-producers (median, 8.5 versus 6, respectively; P= 0.02), re-
gardless of clinical versus surveillance source. In contrast, they were
similar among isolates from active duty personnel (median 7, range
1–24), including those with deployment-related injuries (median 7,
range 1–22), and civilians (median 6.5, range 2–24).
Median virulence scores varied greatly between the 3most common
STs, with ST131 highest (11, range 6–15), ST648 intermediate (7.5,
range 6–11), and ST10 lowest (4, range 2–12). They also varied greatly
by phylogroup, with group B2 highest (12, range 6–24), groups D (8,
range 4–16) and F (7.5, range 6–11) intermediate, and groups A (4,
range 2–12) and B1 (2, range 1–8) lowest.
3.6. Antimicrobial resistance
The proportions of isolates exhibiting resistance to specific antimi-
crobial agents and classes varied significantly by study group
(Table 2). Whether assessed by prevalence or resistance scores, resis-
tance to the studied antimicrobial agents was associated closely with
ESBL status, but minimally with clinical versus surveillance source. All
but one of the isolates with a resistance score ≥6 (n = 39) was ESBL-
positive. Resistance scores were slightly higher among isolates from ci-
vilians (median, 5.5) versus active duty personnel (median, 5.0) (P =
0.09). Among clinical isolates from active duty personnel, resistance
scores were similar regardless of the subject’s deployment-related inju-
ry history (P = 0.45).
3.7. ST131 prevalence comparison with 2011 data from USveterans
A recent study determined that among E. coli clinical isolates from 24
VA medical centers across the U.S. E. coli ST131 (predominantly ST131-
H30) accounted for 7% of fluoroquinolone-susceptible, 78% of
fluoroquinolone-resistant, and 64% of ESBL-producing isolates, and for
28% of E. coli isolates overall (Colpan et al., 2013). Based on the 2% overall
prevalence of ceftriaxone resistance (a proxy for ESBL production) in that
study’s source population (Colpan et al., 2013), back calculations indicat-
ed that ST131 accounted for 26% of that study’s non-ESBL producing E. coli
isolates. Thus, the estimatedprevalence of ST131 among clinical E. coli iso-
lates in that study versus the present study was 64% versus 32% for ESBL-
producing isolates, and 26% versus 24% for non-ESBL-producing isolates.
4. Discussion
In this study we analyzed the clonal background, resistance charac-
teristics, and virulence genotypes of 100 clinical and surveillance E. coli
isolates collected from military personnel and civilians at a US military
medical center. We sought to determine whether distinctive lineages
Table 2
Proportion of Escherichia coli isolates resistant to specific antimicrobial classes and agents.
Resistance prevalence, no. isolates (%)
ESBLa-producers ESBLa-non-producers
Antimicrobial class or agentb Total
(n = 100)
Clinical
(n = 25)
Surveillance
(n = 25)
Clinical
(n = 25)
Surveillance
(n = 25)
Any aminoglycoside 43 (43) 16 (64) 15 (60) 7 (28) 5 (20)
Gentamicin 36 (36) 15 (60) 11 (44) 5 (20) 5 (20)
Amikacin 3 (3) 1 (4) 0 (0) 2 (8) (0)
Tobramycin 35 (35) 14 (56) 13 (52) 6 (24) 2 (8)
Any penicillin 83 (83) 25 (100) 25 (100) 19 (76) 14 (56)
Ampicillin 83 (83) 25 (100) 25 (100) 19 (76) 14 (56)
Ampicillin-sulbactam 68 (68) 25 (100) 25 (100) 12 (48) 6 (24)
Piperacillin-tazobactam 7 (7) 3 (12) 3 (12) 1 (4) 0 (0)
Monobactam (aztreonam) 48 (48) 25 (100) 23 (92) 0 (0) 0 (0)
Any cephalosporin 59 (59) 25 (100) 23 (92) 8 (32) 3 (12)
Cefazolin 59 (59) 25 (100) 23 (92) 8 (32) 3 (12)
Cefepime 49 (49) 25 (100) 23 (92) 1 (4) 0 (0)
Cefoxitin 5 (5) 2 (8) 2 (8) 1 (4) 0 (0)
Ceftazidime 48 (48) 25 (100) 23 (92) 0 (0) 0 (0)
Ceftriaxone 48 (48) 23 (92) 22 (88) 3 (12) n.d.e
Cefuroxime 52 (52) 25 (100) 23 (92) 4 (16) 0 (0)
Any quinolone 58 (58) 21 (84) 16 (64) 13 (52) 8 (32)
Ciprofloxacin 58 (58) 21 (84) 16 (64) 13 (52) 8 (32)
Levofloxacin 57 (57) 21 (84) 16 (64) 12 (48) 8 (32)
Nitrofurans (nitrofurantoin) 2 (2) 1 (4) 1 (4) 0 (0) 0 (0)
Tetracyclines (tetracycline) 68 (68) 18 (72) 24 (96) 12 (48) 14 (56)
Anti-folate agents (TMP-SMZ)c 67 (67) 23 (92) 22 (88) 12 (48) 10 (40)
≥3 antibiotic classes (MDR)d 77 (77) 25 (100) 25 (100) 14 (56) 13 (52)
a ESBL, extended-spectrum beta-lactamase.
b Antimicrobial classes are listed first, followed by the corresponding individual agents that were tested. No resistance was detected to carbapenems (imipenem, meropenem).
c TMP-SMZ, trimethoprim-sulfamethoxazole.
d MDR, multidrug-resistant.
e n.d., not done.
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predominate among such isolates, the degree of similarity between sur-
veillance versus clinical isolates or isolates from active duty personnel
versus civilians, and the comparative prevalence of ST131-H30 in this
population versus among military veterans. The observed clonal distri-
bution largely resembled that expected for North American human
E. coli isolates, with a marked predominance among clinical isolates of
ST131, specifically its H30 subclone (Salipante et al., 2015). ST10 was
more prevalent among clinical isolates than expected, which could be
due to a greater frequency of cutaneous carriage (Table 1). Associations
of resistance and virulence traits with clonal background and ecological
source followed well-established patterns. Thus, ST131-H30 and ST10
contribute importantly to extraintestinal (especially MDR) E. coli infec-
tions among military personnel and associated civilians, possibly justi-
fying special diagnostic and surveillance efforts directed toward them.
Notably, all 4 isolate groups (as defined based on clinical versus sur-
veillance origin and ESBL phenotype) were quite diversemicrobiological-
ly, and their predominant STs were familiar contributors to infections
and/or resistance. As such, we found no evidence of an unrecognized
clonal outbreak or endemic focus, especially one involving a novel E. coli
strain. Although the risk of multidrug-resistant E. coli and ExPEC acquisi-
tion from international settings clearly is high, and outbreaks stemming
from military deployment are critical to the public health of active duty
military members and civilians (CDC, 2004), our findings suggest that
“the usual suspects”, led by ST131-H30, are also prevalent in the military
health system. Thus, any future E. coli rapiddiagnostics developed for gen-
eral use should prove useful also within the military.
The third most common clonal group, ST648, is increasingly report-
ed as an emerging MDR pathogen in the literature (Zhang et al., 2016).
In our study, it accounted for all group F study isolates, andwas linked to
ESBL production among surveillance isolates. However, it contributed
minimally to the clinical isolate population.
A comparison of the present data with the findings of Colpan et al.
regarding clinical E. coli isolates from 24 Veterans Affairs medical
centers in 2011 (Colpan et al., 2013) showed that, here, ST131 and
ST131-H30 accounted for only half as great a proportion of ESBL-
producing isolates (i.e., 32% versus 64%), but a fairly similar proportion
of non-ESBL-producing or total isolates (26% versus 24%). Further
study would be needed to clarify the basis for these findings.
Study limitations include the relatively small sample size and the
limited availability of subject data, which restricted the range of epide-
miological analyses. Study strengths include the unique study popula-
tion and the isolates” extensive molecular characterization.
5. Conclusion
We found a predominance of ST131-H30 and ST10 among clinical
and surveillance E. coli isolates from a military medical center. ST131
andH30were strongly – and uniquely – associatedwith a clinical origin,
irrespective of ESBL status, supporting special pathogenicity for these
lineages, and in comparison with clinical isolates from US military vet-
erans were similarly common overall, although less common among
ESBL-producing isolates. Resistance traits, virulence genes, and clonal/
phylogenetic groups exhibited familiar associations. Our findings pro-
vide potentially useful insights into the clonal distribution and associat-
ed characteristics of E. coli from military personnel and civilians.
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